Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)

The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as Gilead’s bictegravir / emtricitabine/TAF (Biktarvy) and ViiV’s dolutegravir / rilpivirine (Juluca) and dolutegravir/lamivudine (Dovato), which offer improved safety, tolerability, and a lower long-term risk of comorbidities. Long-acting regimens have shown promising results in clinical trials, demonstrating effective viral suppression.Recent approvals of long-acting regimens such as ViiV’s cabotegravir / rilpivirine (Cabenuva) and Gilead’s lenacapavir (Sunlenca, targeting MDR HIV patients) have eliminated the need for lifelong daily pills, mitigating barriers to patient adherence. This report provides a detailed analysis of current medical practices, key unmet needs, and new developments in the HIV space, including oral long acting therapies, along with an analysis of the opportunities and obstacles facing emerging agents.

Questions answered

• How large is the treatable HIV population, and how will diagnosis / drug-treatment rates change over time?
• What is the current state of HIV treatment? What are interviewed experts’ insights into current treatments? What are the key unmet needs in HIV?
• What are KOLs’ perceptions of key emerging therapies, and where do they see these agents fitting into the treatment algorithm?
• What factors drive and constrain the use of branded STRs and multi-tablet regimens in HIV? Which branded therapy is expected to experience the most commercial success during the forecast period?

Geographies: United States, EU5, Japan

Primary research: 18 country-specific interviews with thought-leading infectious disease and internal medicine specialists supported by survey data collected for this and other Clarivate research.

Epidemiology: Number of diagnosed and drug-treated prevalent cases of HIV by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key HIV therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.